Philippe H Marco Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Philippe H Marco.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Philippe H Marco. Philippe H Marco is VP-QA, Clinical & Reg. Affairs in XTENT INC ($XTNT).
Latest Insider Trading Transactions of Philippe H Marco
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.41 | 100 | 141 | 69,800 | 69.9 K to 69.8 K (-0.14 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.40 | 500 | 700 | 69,900 | 70.4 K to 69.9 K (-0.71 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.39 | 300 | 417 | 70,400 | 70.7 K to 70.4 K (-0.42 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.38 | 300 | 414 | 70,700 | 71 K to 70.7 K (-0.42 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.36 | 100 | 136 | 71,000 | 71.1 K to 71 K (-0.14 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.35 | 1,400 | 1,890 | 71,100 | 72.5 K to 71.1 K (-1.93 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.34 | 500 | 670 | 72,500 | 73 K to 72.5 K (-0.68 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.33 | 200 | 266 | 73,000 | 73.2 K to 73 K (-0.27 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.32 | 300 | 396 | 73,200 | 73.5 K to 73.2 K (-0.41 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.31 | 100 | 131 | 73,500 | 73.6 K to 73.5 K (-0.14 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.30 | 800 | 1,040 | 73,600 | 74.4 K to 73.6 K (-1.08 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.25 | 100 | 125 | 74,400 | 74.5 K to 74.4 K (-0.13 %) |
Oct 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.23 | 300 | 369 | 74,500 | 74.8 K to 74.5 K (-0.40 %) |
Sep 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.07 | 100 | 207 | 74,800 | 74.9 K to 74.8 K (-0.13 %) |
Sep 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.05 | 100 | 205 | 74,900 | 75 K to 74.9 K (-0.13 %) |
Sep 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.01 | 350 | 704 | 75,000 | 75.4 K to 75 K (-0.46 %) |
Sep 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.00 | 4,400 | 8,800 | 75,350 | 79.8 K to 75.4 K (-5.52 %) |
Sep 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 1.97 | 50 | 99 | 79,750 | 79.8 K to 79.8 K (-0.06 %) |
Aug 15 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 2.10 | 14,582 | 30,622 | 14,582 | |
Aug 15 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 2.10 | 10,418 | 21,878 | 10,418 | |
Aug 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.60 | 1,000 | 2,600 | 79,800 | 80.8 K to 79.8 K (-1.24 %) |
Aug 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.57 | 100 | 257 | 80,800 | 80.9 K to 80.8 K (-0.12 %) |
Aug 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.56 | 100 | 256 | 80,900 | 81 K to 80.9 K (-0.12 %) |
Aug 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.55 | 2,200 | 5,610 | 81,000 | 83.2 K to 81 K (-2.64 %) |
Aug 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.53 | 100 | 253 | 83,200 | 83.3 K to 83.2 K (-0.12 %) |
Jul 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 2.43 | 3,500 | 8,505 | 83,300 | 86.8 K to 83.3 K (-4.03 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.56 | 500 | 1,780 | 86,800 | 87.3 K to 86.8 K (-0.57 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.52 | 200 | 704 | 87,300 | 87.5 K to 87.3 K (-0.23 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.50 | 200 | 700 | 87,500 | 87.7 K to 87.5 K (-0.23 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.45 | 200 | 690 | 87,700 | 87.9 K to 87.7 K (-0.23 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.44 | 100 | 344 | 87,900 | 88 K to 87.9 K (-0.11 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.43 | 1,700 | 5,831 | 88,000 | 89.7 K to 88 K (-1.90 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.42 | 200 | 684 | 89,700 | 89.9 K to 89.7 K (-0.22 %) |
Jun 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.40 | 400 | 1,360 | 89,900 | 90.3 K to 89.9 K (-0.44 %) |
May 01 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 3.50 | 3,500 | 12,250 | 89,050 | 92.6 K to 89.1 K (-3.78 %) |
Apr 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 5.00 | 13,537 | 67,685 | 13,537 | |
Apr 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 5.00 | 6,769 | 33,845 | 6,769 | |
Apr 02 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 5.00 | 3,500 | 17,500 | 92,550 | 96.1 K to 92.6 K (-3.64 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.49 | 100 | 749 | 96,050 | 96.2 K to 96.1 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.30 | 100 | 730 | 96,150 | 96.3 K to 96.2 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.18 | 100 | 718 | 96,250 | 96.4 K to 96.3 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.16 | 300 | 2,148 | 96,350 | 96.7 K to 96.4 K (-0.31 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.15 | 200 | 1,430 | 96,650 | 96.9 K to 96.7 K (-0.21 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.14 | 200 | 1,428 | 96,850 | 97.1 K to 96.9 K (-0.21 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.12 | 200 | 1,424 | 97,050 | 97.3 K to 97.1 K (-0.21 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.11 | 400 | 2,844 | 97,250 | 97.7 K to 97.3 K (-0.41 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.10 | 100 | 710 | 97,650 | 97.8 K to 97.7 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.07 | 100 | 707 | 97,750 | 97.9 K to 97.8 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.06 | 100 | 706 | 97,850 | 98 K to 97.9 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.01 | 200 | 1,402 | 97,950 | 98.2 K to 98 K (-0.20 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.00 | 300 | 2,100 | 98,150 | 98.5 K to 98.2 K (-0.30 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.95 | 200 | 1,390 | 98,450 | 98.7 K to 98.5 K (-0.20 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.93 | 100 | 693 | 98,650 | 98.8 K to 98.7 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.89 | 100 | 689 | 98,750 | 98.9 K to 98.8 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.87 | 100 | 687 | 98,850 | 99 K to 98.9 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.86 | 400 | 2,744 | 98,950 | 99.4 K to 99 K (-0.40 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.85 | 100 | 685 | 99,350 | 99.5 K to 99.4 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.81 | 100 | 681 | 99,450 | 99.6 K to 99.5 K (-0.10 %) |
Feb 12 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 9.96 | 2,642 | 26,314 | 2,642 | |
Feb 12 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 9.96 | 24,433 | 243,353 | 24,433 | |
Jan 28 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 3,500 | 35,077 | 103,050 | 106.6 K to 103.1 K (-3.28 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.83 | 100 | 983 | 99,550 | 99.7 K to 99.6 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.80 | 100 | 980 | 99,650 | 99.8 K to 99.7 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.79 | 100 | 979 | 99,750 | 99.9 K to 99.8 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 100 | 976 | 99,850 | 100 K to 99.9 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 100 | 976 | 99,950 | 100.1 K to 100 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.75 | 400 | 3,900 | 100,050 | 100.5 K to 100.1 K (-0.40 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.74 | 200 | 1,948 | 100,450 | 100.7 K to 100.5 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.74 | 200 | 1,948 | 100,650 | 100.9 K to 100.7 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.73 | 100 | 973 | 100,850 | 101 K to 100.9 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.72 | 100 | 972 | 100,950 | 101.1 K to 101 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.70 | 100 | 970 | 101,050 | 101.2 K to 101.1 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.69 | 100 | 969 | 101,150 | 101.3 K to 101.2 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.68 | 200 | 1,936 | 101,250 | 101.5 K to 101.3 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.65 | 500 | 4,825 | 101,450 | 102 K to 101.5 K (-0.49 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.53 | 200 | 1,906 | 101,950 | 102.2 K to 102 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.48 | 100 | 948 | 102,150 | 102.3 K to 102.2 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.45 | 200 | 1,890 | 102,250 | 102.5 K to 102.3 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.42 | 300 | 2,826 | 102,450 | 102.8 K to 102.5 K (-0.29 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.41 | 200 | 1,882 | 102,750 | 103 K to 102.8 K (-0.19 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.39 | 100 | 939 | 102,950 | 103.1 K to 103 K (-0.10 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.20 | 100 | 920 | 106,550 | 106.7 K to 106.6 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.14 | 125 | 1,143 | 106,650 | 106.8 K to 106.7 K (-0.12 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.13 | 200 | 1,826 | 106,775 | 107 K to 106.8 K (-0.19 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.12 | 475 | 4,332 | 106,975 | 107.5 K to 107 K (-0.44 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.11 | 100 | 911 | 107,450 | 107.6 K to 107.5 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.08 | 100 | 908 | 107,550 | 107.7 K to 107.6 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.07 | 100 | 907 | 107,650 | 107.8 K to 107.7 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.06 | 100 | 906 | 107,750 | 107.9 K to 107.8 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.05 | 100 | 905 | 107,850 | 108 K to 107.9 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.89 | 400 | 3,956 | 107,950 | 108.4 K to 108 K (-0.37 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.85 | 200 | 1,970 | 108,350 | 108.6 K to 108.4 K (-0.18 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.84 | 200 | 1,968 | 108,550 | 108.8 K to 108.6 K (-0.18 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.79 | 400 | 3,916 | 108,750 | 109.2 K to 108.8 K (-0.37 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 400 | 3,904 | 109,150 | 109.6 K to 109.2 K (-0.37 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.66 | 100 | 966 | 109,550 | 109.7 K to 109.6 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.63 | 100 | 963 | 109,650 | 109.8 K to 109.7 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.62 | 100 | 962 | 109,750 | 109.9 K to 109.8 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.61 | 100 | 961 | 109,850 | 110 K to 109.9 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.60 | 100 | 960 | 109,950 | 110.1 K to 110 K (-0.09 %) |
Dec 27 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.00 | 1,700 | 17,000 | 110,050 | 111.8 K to 110.1 K (-1.52 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.32 | 100 | 932 | 111,750 | 111.9 K to 111.8 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.29 | 100 | 929 | 111,850 | 112 K to 111.9 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.23 | 100 | 923 | 111,950 | 112.1 K to 112 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.22 | 100 | 922 | 112,050 | 112.2 K to 112.1 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.20 | 200 | 1,840 | 112,150 | 112.4 K to 112.2 K (-0.18 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.19 | 100 | 919 | 112,350 | 112.5 K to 112.4 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.18 | 100 | 918 | 112,450 | 112.6 K to 112.5 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.17 | 100 | 917 | 112,550 | 112.7 K to 112.6 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.14 | 200 | 1,828 | 112,650 | 112.9 K to 112.7 K (-0.18 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.12 | 100 | 912 | 112,850 | 113 K to 112.9 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.10 | 1,000 | 9,100 | 112,950 | 114 K to 113 K (-0.88 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.07 | 100 | 907 | 113,950 | 114.1 K to 114 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.05 | 100 | 905 | 114,050 | 114.2 K to 114.1 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.04 | 300 | 2,712 | 114,150 | 114.5 K to 114.2 K (-0.26 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.02 | 100 | 902 | 114,450 | 114.6 K to 114.5 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.01 | 300 | 2,703 | 114,550 | 114.9 K to 114.6 K (-0.26 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.00 | 400 | 3,600 | 114,850 | 115.3 K to 114.9 K (-0.35 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.22 | 100 | 1,022 | 114,000 | 114.1 K to 114 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.17 | 100 | 1,017 | 114,100 | 114.2 K to 114.1 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.13 | 100 | 1,013 | 114,200 | 114.3 K to 114.2 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.11 | 100 | 1,011 | 114,300 | 114.4 K to 114.3 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.10 | 100 | 1,010 | 114,400 | 114.5 K to 114.4 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.06 | 200 | 2,012 | 114,500 | 114.7 K to 114.5 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.03 | 100 | 1,003 | 114,700 | 114.8 K to 114.7 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 100 | 1,002 | 114,800 | 114.9 K to 114.8 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 100 | 1,002 | 114,900 | 115 K to 114.9 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.96 | 100 | 996 | 115,000 | 115.1 K to 115 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.95 | 200 | 1,990 | 115,100 | 115.3 K to 115.1 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.94 | 100 | 994 | 115,300 | 115.4 K to 115.3 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.90 | 1,000 | 9,900 | 115,400 | 116.4 K to 115.4 K (-0.86 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.89 | 200 | 1,978 | 116,400 | 116.6 K to 116.4 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.87 | 100 | 987 | 116,600 | 116.7 K to 116.6 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.86 | 300 | 2,958 | 116,700 | 117 K to 116.7 K (-0.26 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.85 | 100 | 985 | 117,000 | 117.1 K to 117 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.82 | 200 | 1,964 | 117,100 | 117.3 K to 117.1 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.79 | 100 | 979 | 117,300 | 117.4 K to 117.3 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 100 | 976 | 117,400 | 117.5 K to 117.4 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.17 | 100 | 1,017 | 117,500 | 117.6 K to 117.5 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.16 | 100 | 1,016 | 117,600 | 117.7 K to 117.6 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.15 | 100 | 1,015 | 117,700 | 117.8 K to 117.7 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.11 | 100 | 1,011 | 117,800 | 117.9 K to 117.8 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.10 | 100 | 1,010 | 117,900 | 118 K to 117.9 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.07 | 200 | 2,014 | 118,000 | 118.2 K to 118 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 200 | 2,004 | 118,200 | 118.4 K to 118.2 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.01 | 200 | 2,002 | 118,400 | 118.6 K to 118.4 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.00 | 2,400 | 24,000 | 118,600 | 121 K to 118.6 K (-1.98 %) |
Oct 18 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.01 | 3,500 | 35,035 | 121,000 | 124.5 K to 121 K (-2.81 %) |
Oct 02 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.51 | 200 | 1,702 | 124,500 | 124.7 K to 124.5 K (-0.16 %) |
Oct 02 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.50 | 3,300 | 28,050 | 124,700 | 128 K to 124.7 K (-2.58 %) |